Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alicapistat
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alicapistat (ABT-957) is an orally active, selective small molecule inhibitor of human calpains 1 and 2, which are calcium-dependent cysteine proteases. It was developed for the potential treatment of Alzheimer's disease. The drug acts by inhibiting calpain activity, which is implicated in neurodegenerative processes including those seen in Alzheimer's disease. Alicapistat was originally developed by Abbott Laboratories and later by AbbVie. Clinical development was discontinued after phase 1 trials due to insufficient central nervous system target engagement[2][6][3][5].
- Other names
- alicapistat1254698-46-8BWF3F50KF8BWF-3F50KF8BWF 3F50KF8
02
Targets
CAPN (Schistosoma calpain large subunit family)
Beyond the preview
Go deeper on alicapistat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alicapistat.